PMID- 35063813
OWN - NLM
STAT- Publisher
LR  - 20231019
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 17
DP  - 2022 Mar
TI  - iNKT: A new avenue for CAR-based cancer immunotherapy.
PG  - 101342
LID - S1936-5233(22)00004-3 [pii]
LID - 10.1016/j.tranon.2022.101342 [doi]
LID - 101342
AB  - Chimeric antigen receptor (CAR) T cell is a T lymphocyte-based immunotherapy, 
      which achieves great successes in treating blood malignancies and provides new 
      hope to cue advanced cancer patients. Invariant natural killer T (iNKT) cells are 
      a kind of special T lymphocytes characterized by expressing invariant TCR of 
      Valpha24Vbeta11 to recognize CD1d-presented glycolipid antigens, which bridge innate and 
      adaptive immune responses. iNKT cells themselves show strong anti-tumor effect in 
      tumor models via CD1d-mediated killing of CD1d-positive tumor cells and 
      immunosuppressive TAMs and MDSCs, and are closely related to the prognosis of 
      cancer patients. iNKT cells are not restricted to polymorphic human leukocyte 
      antigen (HLA) and can prevent Graft versus Host Disease (GvHD), which makes it to 
      be an ideal CAR vector for allogeneic therapy. Although CAR-iNKT was developed 
      and verified by several different teams and attracts more and more attentions, 
      many obstacles are still needed to be resolved before obtaining CAR-iNKT 
      therapeutics. In this review, we summarized the current status of clinical 
      application of iNKT cells and the latest achievements of CAR-iNKT cells, which 
      provides new insight in CAR-iNKT development and usages.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Liu, Yilin
AU  - Liu Y
AD  - Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China.
FAU - Wang, Gang
AU  - Wang G
AD  - Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China; 
      Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu 221002, PR China; Jiangsu Center for the 
      Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou 
      Medical University, Xuzhou, Jiangsu 221002, PR China.
FAU - Chai, Dafei
AU  - Chai D
AD  - Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China; 
      Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu 221002, PR China; Jiangsu Center for the 
      Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou 
      Medical University, Xuzhou, Jiangsu 221002, PR China.
FAU - Dang, Yuanyuan
AU  - Dang Y
AD  - Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China.
FAU - Zheng, Junnian
AU  - Zheng J
AD  - Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu 221002, PR China; Jiangsu Center for the 
      Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou 
      Medical University, Xuzhou, Jiangsu 221002, PR China. Electronic address: 
      jnzheng@xzhmu.edu.cn.
FAU - Li, Huizhong
AU  - Li H
AD  - Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China; 
      Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu 221002, PR China; Jiangsu Center for the 
      Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou 
      Medical University, Xuzhou, Jiangsu 221002, PR China. Electronic address: 
      lhz@xzhmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220118
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC8784340
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - Chimeric Antigen Receptor (CAR)
OT  - Cytokines
OT  - Invariant Natural Killer T (iNKT) cells
COIS- The authors confirm that there are no potential conflict of interest to disclose.
EDAT- 2022/01/23 06:00
MHDA- 2022/01/23 06:00
PMCR- 2022/01/18
CRDT- 2022/01/22 05:39
PHST- 2022/01/07 00:00 [received]
PHST- 2022/01/07 00:00 [accepted]
PHST- 2022/01/23 06:00 [pubmed]
PHST- 2022/01/23 06:00 [medline]
PHST- 2022/01/22 05:39 [entrez]
PHST- 2022/01/18 00:00 [pmc-release]
AID - S1936-5233(22)00004-3 [pii]
AID - 101342 [pii]
AID - 10.1016/j.tranon.2022.101342 [doi]
PST - ppublish
SO  - Transl Oncol. 2022 Mar;17:101342. doi: 10.1016/j.tranon.2022.101342. Epub 2022 
      Jan 18.